Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-338 (Acotiamide) Efficacy in Functional Dyspepsia
NCT00761358Phase 3Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Sep 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in functional dyspepsia (FD) comparing Z-338 with Placebo (2 arms). Primary endpoints: General impression at last visit in treatment period at 4 weeks and Elimination rate of post-prandial fullness, upper abdominal bloating and early satiety at 4 weeks. Started Sep 2008; status: completed.
02
Drugs
acotiamide
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT00761358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00761358.